Benchling has launched its inaugural 2023 State of Tech in Biopharma report, which has shed light on the obstacles that biopharma encounter when striving to fully implement and embrace these technologies. 

The report surveyed 300 R&D and IT experts from biopharma companies large and small to do a first-ever investigation into biopharma’s use of an enabling tech stack — consisting of robotics and automation, connected instruments, R&D data platforms, cloud-based...